Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of the American Society for Mass Spectrometry|January 5, 2002
Development of generic liquid chromatography-mass spectrometry methods using experimental designCarmai Seto, Kevin P Bateman, Berton GunterPharmaceutical Research|February 27, 2008
Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometryJinsong Ni, Hui Ouyang, Mauro Aiello, et al.Bioanalysis|November 19, 2010
Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MSJinsong Ni, Hui Ouyang, Carmai Seto, et al.Chemical Research in Toxicology|October 19, 2004
Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometryKevin P Bateman, Jennifer Baker, Mark Wilke, et al.Bioorganic & Medicinal Chemistry Letters|November 11, 2006
In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolitesDeborah A Nicoll-Griffith, Carmai Seto, Yves Aubin, et al.Bioorganic & Medicinal Chemistry Letters|April 10, 2007
Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent bindingJean-François Lévesque, Stephen H Day, Nathalie Chauret, et al.Journal of Medicinal Chemistry|February 3, 2006
Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin KSheldon N Crane, W Cameron Black, James T Palmer, et al.Bioorganic & Medicinal Chemistry Letters|January 30, 2008
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin KJacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish, et al.Bioorganic & Medicinal Chemistry Letters|January 12, 2010
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitorElise Isabel, Kevin P Bateman, Nathalie Chauret, et al.Journal of Medicinal Chemistry|February 16, 2007
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)Claudio F Sturino, Gary O'Neill, Nicolas Lachance, et al.Pageof 1